Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 9/20 | 0.63 |
| ▸ | RAB9A | P51151 | 9/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.63 |
| ▸ | MAPT | P10636 | 6/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.59 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.58 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.58 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.58 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.55 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.55 |
| ▸ | RELA | Q04206 | 2/20 | 0.55 |
| ▸ | PPARG | P37231 | 1/20 | 0.55 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.55 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.55 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28033825 | 0.83 | NPC1 (0.61) | NPC1RAB9AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL28033278 | 0.83 | ALDH1A1 (0.48) | NPC1RAB9AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL28033274 | 0.81 | RAB9A (0.57) | NPC1RAB9AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL10768583 | 0.79 | HPGD (0.57) | NPC1RAB9AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL28033272 | 0.79 | NPC1 (0.43) | NPC1RAB9AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL31063900 | 0.79 | CSNK2A1 (0.42) | NPC1RAB9AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL28033271 | 0.78 | CES2 (0.44) | NPC1RAB9AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL176007 | 0.78 | NPC1 (0.66) | NPC1RAB9AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL28033321 | 0.78 | GAA (0.51) | RAB9AALDH1A1MAPTLMNAHPGD | |
| SCHEMBL12788381 | 0.77 | NPC1 (1.00) | NPC1RAB9AALDH1A1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4496727-A | ORGANIC PIGMENTS; PLASTICS; LACQUERS; INKS; COATINGS; COLOR FASTNESS | CIBA-GEIGY CORPORATION (US) | 1985-01-29 | — | — | US | claimed |
| US-4385174-A | FOR PIGMENTS | CIBA-GEIGY CORPORATION (US) | 1983-05-24 | — | — | US | claimed |
| US-4349671-A | Process for the production of metal complexes of isoindoline azines | CIBA-GEIGY CORPORATION (US) | 1982-09-14 | — | — | US | claimed |
| US-20260027089-A1 | MrgprX2 Antagonists for the Treatment of Inflammatory Disorders | DERMIRA INC (US) | 2026-01-29 | — | — | US | disclosed |
| US-12502380-B2 | MrgprX2 antagonists for the treatment of inflammatory disorders | DERMIRA, INC. (US) | 2025-12-23 | — | — | US | disclosed |
| EP-4662211-A1 | G PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2) DEGRADATION COMPOUNDS AND USE THEREOF | Nanjing Huanbo Biotechnology Co., Ltd. (CN) | 2025-12-17 | — | — | EP | disclosed |
| US-20250057816-A1 | MrgprX2 Antagonists for the Treatment of Inflammatory Disorders | DERMIRA, INC. | 2025-02-20 | — | — | US | disclosed |
| CN-114845709-B | MRGPRX2 antagonists for the treatment of inflammatory disorders | 德米拉公司 | 2024-10-01 | — | — | CN | disclosed |
| WO-2024165075-A1 | G PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2) DEGRADATION COMPOUNDS AND USE THEREOF | NANJING HUANBO BIOTECHNOLOGY CO., LTD. (CN) | 2024-08-15 | — | — | WO | disclosed |
| US-20230029266-A1 | MrgprX2 Antagonists for the Treatment of Inflammatory Disorders | DERMIRA, INC. | 2023-01-26 | — | — | US | disclosed |
| EP-4054554-A1 | MRGPRX2 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | Dermira, Inc (US) | 2022-09-14 | — | — | EP | disclosed |
| US-5627198-A | BLOOD METAL CONCENTRATIONS | HAFSLUND NYCOMED PHARMA AKTIENGESELLSCHAFT (AT) | 1997-05-06 | — | — | US | disclosed |
| EP-0716087-A1 | Heterocyclic amides for control of the potassium channels | Hafslund Nycomed Pharma AG (AT) | 1996-06-12 | — | — | EP | disclosed |
| US-4237293-A | COLORFAST SHADES OF YELLOW TO RED FOR PLASTICS AND LACQUERS | CIBA-GEIGY CORPORATION (US) | 1980-12-02 | — | — | US | disclosed |
| US-4237286-A | COLORING PLASTICS AND LACQUERS IN YELLOW TO RED SHADES | CIBA-GEIGY CORPORATION (US) | 1980-12-02 | — | — | US | disclosed |
| US-4237292-A | SHADES OF YELLOW TO RED FOR PLASTICS AND LACQUERS | CIBA-GEIGY CORPORATION (US) | 1980-12-02 | — | — | US | disclosed |
| US-4132708-A | Metal complexes of azomethines and process for their manufacture | CIBA-GEIGY CORPORATION (US) | 1979-01-02 | — | — | US | disclosed |
| US-4118384-A | DIAZOTIZATION | BAYER AKTIENGESELLSCHAFT (DE) | 1978-10-03 | — | — | US | disclosed |
| US-4111947-A | DYES, PLASTICS, LACQUERS | CIBA-GEIGY CORPORATION (US) | 1978-09-05 | — | — | US | disclosed |
| US-4022770-A | COLORING | CIBA-GEIGY CORPORATION (US) | 1977-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260027089-A1 | MrgprX2 Antagonists for the Treatment of Inflammatory Disorders | MRGPRX2, MRGPRX1, MRGPRX4 | NPC1 261/4885RAB9A 3183/4885ALDH1A1 1299/4885 |
| US-12502380-B2 | MrgprX2 antagonists for the treatment of inflammatory disorders | MRGPRX2, MRGPRX1, MRGPRX4 | NPC1 575/4885RAB9A 1759/4885ALDH1A1 3145/4885 |
| US-20250057816-A1 | MrgprX2 Antagonists for the Treatment of Inflammatory Disorders | MRGPRX2, MRGPRX1, MRGPRX4 | NPC1 575/4885RAB9A 1759/4885ALDH1A1 3145/4885 |
| US-20230029266-A1 | MrgprX2 Antagonists for the Treatment of Inflammatory Disorders | MRGPRX2, MRGPRX1, MRGPRX4 | NPC1 575/4885RAB9A 1759/4885ALDH1A1 3145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.